<!--
title: Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children
description: DOI: 10.1001/jamacardio.2021.3471
published: true
date: 2022-02-11T09:58:12.664Z
tags: side, effects, effect, risk, mrna, adverse, bnt162b2, heart, myocarditis, rna, messanger, children
editor: ckeditor
dateCreated: 2022-02-11T09:57:34.563Z
-->

<p>JAMA Cardiol</p>
<p>. 2021 Dec 1;6(12):1446-1450.</p>
<p>doi: 10.1001/jamacardio.2021.3471.</p>
<h1><strong>Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children</strong></h1>
<p><a href="https://pubmed.ncbi.nlm.nih.gov/?term=Dionne+A&amp;cauthor_id=34374740">Audrey Dionne</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Sperotto+F&amp;cauthor_id=34374740">Francesca Sperotto</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Chamberlain+S&amp;cauthor_id=34374740">Stephanie Chamberlain</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Baker+AL&amp;cauthor_id=34374740">Annette L Baker</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Powell+AJ&amp;cauthor_id=34374740">Andrew J Powell</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Prakash+A&amp;cauthor_id=34374740">Ashwin Prakash</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Castellanos+DA&amp;cauthor_id=34374740">Daniel A Castellanos</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Saleeb+SF&amp;cauthor_id=34374740">Susan F Saleeb</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=de+Ferranti+SD&amp;cauthor_id=34374740">Sarah D de Ferranti</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Newburger+JW&amp;cauthor_id=34374740">Jane W Newburger</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a>,&nbsp;<a href="https://pubmed.ncbi.nlm.nih.gov/?term=Friedman+KG&amp;cauthor_id=34374740">Kevin G Friedman</a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-1"><sup>1</sup></a><sup>&nbsp;</sup><a href="https://pubmed.ncbi.nlm.nih.gov/34374740/#affiliation-2"><sup>2</sup></a></p>
<p>Affiliations expand</p>
<ul>
  <li>PMID: <strong>34374740</strong></li>
  <li>PMCID: <strong>PMC8356143</strong> (available on 2022-08-10)</li>
  <li>DOI: <a href="https://doi.org/10.1001/jamacardio.2021.3471">10.1001/jamacardio.2021.3471</a></li>
</ul>
<h2><strong>Abstract</strong></h2>
<p><strong>Importance: </strong>The BNT162b2 (Pfizer-BioNTech) messenger RNA COVID-19 vaccine was authorized on May 10, 2021, for emergency use in children aged 12 years and older. Initial reports showed that the vaccine was well tolerated without serious adverse events; however, cases of myocarditis have been reported since approval.</p>
<p><strong>Objective: </strong>To review results of comprehensive cardiac imaging in children with myocarditis after COVID-19 vaccine.</p>
<p><strong>Design, setting, and participants: </strong>This study was a case series of children younger than 19 years hospitalized with myocarditis within 30 days of BNT162b2 messenger RNA COVID-19 vaccine. The setting was a single-center pediatric referral facility, and admissions occurred between May 1 and July 15, 2021.</p>
<p><strong>Main outcomes and measures: </strong>All patients underwent cardiac evaluation including an electrocardiogram, echocardiogram, and cardiac magnetic resonance imaging.</p>
<p><strong>Results: </strong>Fifteen patients (14 male patients [93%]; median age, 15 years [range, 12-18 years]) were hospitalized for management of myocarditis after receiving the BNT162b2 (Pfizer) vaccine. Symptoms started 1 to 6 days after receipt of the vaccine and included chest pain in 15 patients (100%), fever in 10 patients (67%), myalgia in 8 patients (53%), and headache in 6 patients (40%). Troponin levels were elevated in all patients at admission (median, 0.25 ng/mL [range, 0.08-3.15 ng/mL]) and peaked 0.1 to 2.3 days after admission. By echocardiographic examination, decreased left ventricular (LV) ejection fraction (EF) was present in 3 patients (20%), and abnormal global longitudinal or circumferential strain was present in 5 patients (33%). No patient had a pericardial effusion. Cardiac magnetic resonance imaging findings were consistent with myocarditis in 13 patients (87%) including late gadolinium enhancement in 12 patients (80%), regional hyperintensity on T2-weighted imaging in 2 patients (13%), elevated extracellular volume fraction in 3 patients (20%), and elevated LV global native T1 in 2 patients (20%). No patient required intensive care unit admission, and median hospital length of stay was 2 days (range 1-5). At follow-up 1 to 13 days after hospital discharge, 11 patients (73%) had resolution of symptoms. One patient (7%) had persistent borderline low LV systolic function on echocardiogram (EF 54%). Troponin levels remained mildly elevated in 3 patients (20%). One patient (7%) had nonsustained ventricular tachycardia on ambulatory monitor.</p>
<p><strong>Conclusions and relevance: </strong>In this small case series study, myocarditis was diagnosed in children after COVID-19 vaccination, most commonly in boys after the second dose. In this case series, in short-term follow-up, patients were mildly affected. The long-term risks associated with postvaccination myocarditis remain unknown. Larger studies with longer follow-up are needed to inform recommendations for COVID-19 vaccination in this population.</p>
<p>&nbsp;</p>
<p>Source: https://pubmed.ncbi.nlm.nih.gov/34374740/</p>
